Key Segmentation
By Product
-
Assay Kits
-
Instruments
-
Services
By Biomarkers
-
Circulating Tumor Cells (CTCs)
-
Circulating Cell-Free DNA (cfDNA)
-
Extracellular Vesicles (EVs)
-
Other Circulating Biomarkers
By Application
-
Early Detection/Screening
-
Diagnosis
-
Treatment Selection
-
Monitoring
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market is expected to grow at a CAGR of 8.61% from 2026 to 2035.
The Breast Cancer Liquid Biopsy Market was valued at USD 1.33 Billion in 2025.
The growing shift toward precision oncology with more than 70% of oncologists using liquid biopsy for treatment guidance, and FDA companion diagnostic approval expansion for PIK3CA, HER2, ESR1, and BRCA mutation detection.
Circulating cell-free DNA (cfDNA) dominated with approximately 50.7% share in 2025.
North America dominated the Breast Cancer Liquid Biopsy Market in 2025.